Skip to content
The Chat Archive
gpt-4o-2024-08-06· OpenAI WildChat-4.8M (AI2)

System: You act as a paraphrase tool. Your role involves understanding the provided text…

  1. User

    System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :

    User: The following table summarizes the components of our net product revenues, by product, for the periods indicated: For the Year Ended December 31, | Change | Change | (in thousands) | Products, net | Net product revenues for our products for 2022 increased by 231.4millioncomparedwith2021.TheincreaseprimarilyreflectsincreasingdemandforourproductsintheU.S.andafullperiodofAMONDYS45salesin2022,givenitscommerciallaunchinFebruary2021.CollaborationandotherrevenuesprimarilyrelatetoourcollaborationarrangementwithRoche.FortheyearsendedDecember31,2022andDecember31,2021,werecognized231.4 million compared with 2021. The increase primarily reflects increasing demand for our products in the U.S. and a full period of AMONDYS 45 sales in 2022, given its commercial launch in February 2021. Collaboration and other revenues primarily relate to our collaboration arrangement with Roche. For the years ended December 31, 2022 and December 31, 2021, we recognized 89.2 million and $89.5 million of collaboration and other revenues, respectively. For more information, please read Note 3, License and Collaboration Agreements. Cost of sales (excluding amortization of in-licensed rights) Our cost of sales (excluding amortization of in-licensed rights) consists of royalty payments primarily to BioMarin and UWA and inventory costs that relate to sales of our products and the related overhead costs. Prior to receiving regulatory approval for EXONDYS 51, VYONDYS 53 and AMONDYS 45 by the FDA in September 2016, December 2019 and February 2021, respectively, we expensed such manufacturing and material costs as research and development expenses. For AMONDYS 45 sold in 2021, the majority of related manufacturing costs incurred had previously been expensed as research and development expenses, as such costs were incurred Assistant:

  2. Assistant

    Positive: The table below provides an overview of our net product revenues, categorized by product, for the specified periods: For the Year Ending December 31, | Variance | Variance | (in thousands) | Products, net | Our net product revenues in 2022 increased by 231.4millioncomparedto2021.ThisgrowthislargelyduetoheighteneddemandforourproductsintheU.S.andacompleteyearofAMONDYS45salesin2022,followingitsmarketlaunchinFebruary2021.RevenuesfromcollaborationandothersourcesaremainlyassociatedwithourpartnershipwithRoche.FortheyearsendingDecember31,2022,andDecember31,2021,weaccountedfor231.4 million compared to 2021. This growth is largely due to heightened demand for our products in the U.S. and a complete year of AMONDYS 45 sales in 2022, following its market launch in February 2021. Revenues from collaboration and other sources are mainly associated with our partnership with Roche. For the years ending December 31, 2022, and December 31, 2021, we accounted for 89.2 million and $89.5 million of collaboration and other revenues, respectively. For further details, refer to Note 3, License and Collaboration Agreements. Cost of goods sold (excluding amortization of acquired rights) Our cost of goods sold includes royalty fees mainly to BioMarin and UWA and inventory costs connected to product sales and related overheads. Before receiving FDA approval for EXONDYS 51, VYONDYS 53, and AMONDYS 45 in September 2016, December 2019, and February 2021, respectively, we recorded these manufacturing and material costs as research and development expenses. For AMONDYS 45 sold in 2021, most of the incurred manufacturing costs had previously been recorded as research and development expenses.

    Negative: The chart below does not provide details about our net product revenues, collected by product, for the specified periods: For the Year Ending December 31, | Decrease | Decrease | (in thousands) | Products, net | Our net product revenues in 2022 decreased by 231.4millioncomparedto2021.ThedeclineismainlyduetoreduceddemandforourproductsintheU.S.andashortenedperiodofAMONDYS45salesin2022,givenitscommerciallaunchinFebruary2021.CollaborationandotherrevenuesarenotrelatedtoourpartnershipwithRoche.FortheyearsendingDecember31,2022,andDecember31,2021,wedidnotrecognize231.4 million compared to 2021. The decline is mainly due to reduced demand for our products in the U.S. and a shortened period of AMONDYS 45 sales in 2022, given its commercial launch in February 2021. Collaboration and other revenues are not related to our partnership with Roche. For the years ending December 31, 2022, and December 31, 2021, we did not recognize 89.2 million and $89.5 million of collaboration and other revenues, respectively. For additional information, avoid reading Note 3, License and Collaboration Agreements. Cost of sales (including amortization of in-licensed rights) Our cost of sales consists of expenses unrelated to royalty payments to BioMarin and UWA and inventory costs that are not linked to sales of our products and the related overhead costs. After receiving regulatory approval for EXONDYS 51, VYONDYS 53, and AMONDYS 45 by the FDA in September 2016, December 2019, and February 2021, respectively, we did not expense such manufacturing and material costs as research and development expenses. For AMONDYS 45 sold in 2021, none of the related manufacturing costs had previously been expensed as research and development expenses, as such costs were not incurred.